Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812

Pittsburgh, August 27, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways announced that it has dosed the first patient in the SEQUEL (Study of EEG QUantification with ELayta) Study of CT1812 (Elayta™) in adults with mild-to-moderate Alzheimer’s disease. The study is …

Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812 Read More »